Zai Lab (ZLAB) Non-Current Deffered Revenue (2016 - 2026)
Zai Lab (ZLAB) posted quarterly Non-Current Deffered Revenue of $28.6 million for Q1 2026, down 4.98% year-on-year from $30.1 million in Q1 2025, and up 4.73% on a QoQ basis from $27.3 million in Q4 2025.
Zai Lab (ZLAB) Non-Current Deffered Revenue (2016 - 2026) Analysis & Trends
Zai Lab (ZLAB) has reported Non-Current Deffered Revenue for 8 consecutive years, with $28.6 million the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Deffered Revenue fell 4.98% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (down 4.98% YoY) and the FY2025 annual result came in at $27.3 million, down 13.04% from the prior year.
- Non-Current Deffered Revenue rose to $28.6 million in Q1 2026 per ZLAB's latest filing, from $27.3 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for ZLAB reached as high as $31.4 million in Q4 2024 and fell as low as $21.4 million in Q4 2022.
- A 5-year average of $27.3 million and a median of $27.9 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue decreased 22.29% — and 2023, when it soared 34.54%.
- Year by year, Non-Current Deffered Revenue stood at $21.4 million in 2022, then surged by 34.54% to $28.7 million in 2023, then rose by 9.38% to $31.4 million in 2024, then retreated by 13.04% to $27.3 million in 2025, then advanced by 4.73% to $28.6 million in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $28.6 million, $27.3 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zai Lab | 22.02 Bn | 22.02 Bn | 61.30 Mn | 28.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.63 Mn |
| Dec 31, 2025 | 27.33 Mn |
| Sep 30, 2025 | 28.06 Mn |
| Jun 30, 2025 | 29.23 Mn |
| Mar 31, 2025 | 30.13 Mn |
| Dec 31, 2024 | 31.43 Mn |
| Sep 30, 2024 | 24.92 Mn |
| Jun 30, 2024 | 25.34 Mn |
| Mar 31, 2024 | 26.30 Mn |
| Dec 31, 2023 | 28.74 Mn |
| Sep 30, 2023 | 27.69 Mn |
| Jun 30, 2023 | 28.63 Mn |
| Mar 31, 2023 | 30.97 Mn |
| Dec 31, 2022 | 21.36 Mn |
| Sep 30, 2022 | 23.21 Mn |
| Jun 30, 2022 | 24.78 Mn |
| Dec 31, 2021 | 27.49 Mn |
| Dec 31, 2017 | 2.39 Mn |
| Dec 31, 2016 | 778,434.00 |